Two-phase mendelian randomization reveals causal associations with plasma proteins in inflammatory bowel disease, indicating potential therapeutic targets.
Key Points
The study identifies proteins significantly associated with inflammatory bowel disease risk, validating findings across cohorts.
A two-phase approach utilized summary-data‐based mendelian randomization, highlighting genes associated with Crohn's disease and ulcerative colitis.
Machine learning models indicated potential therapeutic targets, such as glucokinase regulatory protein and hepatocyte growth factor-like protein.
Findings contribute to precision medicine through improved diagnosis and treatment of inflammatory bowel disease, with noted limitations in diverse population validation.